Clinical Trials Browser

Withdrawn × Interventional × Biopsy × Clear all

NCT07082270 2026-05-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT07498465 2026-05-05

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07211204 2026-03-03

Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population

Phase NA Withdrawn

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Atypical Squamous Cells of the Cervix

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06730100 2025-10-06

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06670976 2025-08-26

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

Phase 1 Withdrawn

Sarcoma

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Phase 1/2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT05539365 2025-01-29

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT06206876 2025-01-17

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Withdrawn

Neoplasm Metastasis

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05518032 2024-09-26

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Phase 1/2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06400264 2024-05-06

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Phase 2 Withdrawn

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Prostatic Neoplasms

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Phase 2 Withdrawn

Anatomic Stage III Breast Cancer AJCC v8

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT05327738 2022-12-14

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT05244434 2022-06-09

Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer

Phase NA Withdrawn

Advanced Breast Adenocarcinoma

NCT03397186 2019-09-10

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Phase 2 Withdrawn

Sarcoma, Liposarcoma, Myxoid

NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

Phase 2 Withdrawn

GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

NCT02817607 2019-05-07

Study to Assess Breast Sensation Before and After Breast Cancer Treatment

Phase NA Withdrawn

Carcinoma, Intraductal, Noninfiltrating

NCT03166254 2019-04-12

Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02610920 2019-03-26

Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection

Phase EARLY_PHASE1 Withdrawn

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Ductal, Breast

NCT00996749 2018-07-03

Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Phase NA Withdrawn

Prostatic Neoplasms

NCT01821196 2018-03-12

Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma

Phase NA Withdrawn

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03238664 2018-01-02

Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors

Phase NA Withdrawn

Carcinoma, Transitional Cell

NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Phase EARLY_PHASE1 Withdrawn

Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis

NCT02628496 2016-09-09

Confocal Laser Microlaryngoscopy (CLMx)

Phase NA Withdrawn

Laryngeal Neoplasms

NCT02705339 2016-05-17

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00661336 2015-03-13

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

Phase 1 Withdrawn

Melanoma

NCT01403103 2014-01-17

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

Phase EARLY_PHASE1 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00796874 2013-07-25

Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

Phase NA Withdrawn

Prostatic Neoplasms

NCT00005790 2012-06-11

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

Phase NA Withdrawn

Astrocytoma, Craniopharyngioma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Oligodendroglioma, Pinealoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma

NCT01209013 2012-05-08

Oedisse

Phase 3 Withdrawn

Gastrointestinal

Barrett Esophagus

NCT01409226 2012-04-05

3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women

Phase NA Withdrawn

Breast Neoplasms, Disease

NCT00451945 2008-06-18

New Indications for Ultrasound in the Staging of Cervical Cancer

Phase NA Withdrawn

Uterine Cervical Neoplasms